Application and progress of cyclosporine A in ocular surface diseases
10.3980/j.issn.1672-5123.2024.6.09
- VernacularTitle:环孢素A在眼表疾病中的应用及进展
- Author:
Yue LI
1
,
2
,
3
,
4
;
Jinfen LI
1
,
2
,
3
,
4
;
Hui HUANG
1
,
2
,
3
,
4
;
Qianqian LAN
1
,
2
,
3
,
4
;
Fan XU
1
,
2
,
3
,
4
;
Li JIANG
1
,
2
,
3
,
4
Author Information
1. The People's Hospital of Guangxi Zhuang Autonomous Region
2. Guangxi Key Laboratory of Eye Health
3. Guangxi Health Commission Key Laboratory of Ophthalmology and Related Systemic Diseases Artificial Intelligence Screening Technology
4. Institute of Ophthalmic Diseases, Guangxi Academy of Medical Sciences, Nanning 530021, Guangxi Zhuang Autonomous Region, China
- Publication Type:Journal Article
- Keywords:
cyclosporine A;
ocular surface diseases;
inflammation
- From:
International Eye Science
2024;24(6):890-894
- CountryChina
- Language:Chinese
-
Abstract:
Cyclosporine A, a cyclic polypeptide, exhibits potent immunosuppressive activity and exerts its effects through various mechanisms including immunosuppression, anti-inflammatory, inhibition of apoptosis, promotion of epithelial healing and goblet cell function recovery, enhancement of tear secretion, and close association with ocular surface disease repair. Owing to its significant efficacy, inhibition of disease recurrence and few side effects, the clinical application of cyclosporine A in the management of ocular surface diseases, including dry eye, corneal graft rejection following penetrating keratoplasty, vernal keratoconjunctivitis, noninfective keratitis and herpes simplex virus keratitis, has witnessed a substantial rise in recent years. Nevertheless, variations exist in the management of ocular surface inflammatory diseases when utilizing distinct concentrations and dosage forms of cyclosporine A. Therefore, the paper provides an overview of impacts of cyclosporine A on ocular surface diseases.
